Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Oppenheimer analyst Jay Olson maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $15.85.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. ( LBE) announced that the 500 th lung transplant utilizing LBE’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung transplant utilizing LBE’s ...

A trust created while an individual is still alive is an inter vivos trust (living trust), while one established upon the death of the individual is a testamentary trust (will trust). Trusts are ...

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in ...

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in ...

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development. New investor Bedford Ridge Capital and existing ...